

## Special Issue

# Tuberculosis Drug Discovery and Development

### Message from the Guest Editors

According to the World Health Organization, tuberculosis, caused by *Mycobacterium tuberculosis*, is an infectious disease that causes the highest number of deaths worldwide. Standard treatments with antibiotics are long and complex, and drug resistance is growing rapidly: even for recently approved bedaquiline, delamanid, and linezolid, resistance has already emerged. Thus, there is a great unmet medical need and, consequently, a great interest in the opportunities and challenges associated with tackling tuberculosis, in order to develop effective and, possibly, cheap antimycobacterial agents endowed with new mechanisms of action. This issue will cover multiple aspects of the search for new molecules starting both from natural and synthetic compounds and addressing different or multiple targets (multitarget drugs) in *Mycobacterium tuberculosis*. Original research articles, as well as reviews, that are able to make substantial advances in this field are welcome.

### Guest Editors

Prof. Dr. Luca Costantino

Università degli Studi di Modena e Reggio Emilia, Dipartimento di Scienze della Vita, Modena, Italy

Dr. Fiorella Meneghetti

Department of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy

### Deadline for manuscript submissions

closed (30 September 2019)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/21860](https://mdpi.com/si/21860)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).